Is Biochemical Response More Important Than Duration of Neoadjuvant Hormone Therapy Before Radiotherapy for Clinically Localized Prostate Cancer? An Analysis of the 3- Versus 8-Month Randomized Trial

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 1, 2010, Pages 23-30

  Alexander, Abraham ^a   Crook, Juanita ^b   Jones, Stuart ^a   Malone, Shawn ^c   Bowen, Julie ^d   Truong, Pauline ^a   Pai, Howard ^a   Ludgate, Charles ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d Northeastern Ontario Regional Cancer Centre   (Canada)

Author keywords

Neoadjuvant androgen deprivation therapy (ADT); Prostate cancer; Prostate radiotherapy; Prostate specific antigen (PSA)

Indexed keywords

BIOCHEMICAL DISEASE-FREE SURVIVAL (BDFS); BIOCHEMICAL RESPONSE; COMBINED THERAPY; CRITICAL DETERMINANT; DEPRIVATION THERAPY; GLEASON SCORES; HIGH-RISK PATIENTS; INDEPENDENT PREDICTORS; LOCALIZED PROSTATE CANCER; MULTI VARIATE ANALYSIS; MULTI-MODAL; NEOADJUVANT HORMONE THERAPY; PROSTATE CANCERS; PROSTATE RADIOTHERAPY; PROSTATE SPECIFIC ANTIGEN; RANDOMIZED TRIAL; UNIVARIATE ANALYSIS;

ANTIGENS; DECISION MAKING; FLUORINE CONTAINING POLYMERS; MULTIVARIANT ANALYSIS; RADIOTHERAPY; RISK ANALYSIS;

PEELING;

FLUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE-FREE SURVIVAL; FLUTAMIDE; GOSERELIN; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 72049125325     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.01.030     Document Type: Article

References (25)

1. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external beam radiotherapy in patients with locally advanced prostate cancer (an EORTC study): A phase II randomized trial. Lancet 340 (2002) 103-106
2. Hanks G.E., Pajak T.F., Porter A., et al. A phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group protocol 92-02. J Clin Onol 21 (2003) 3972-3978
3. Roach M., Bae K., Pilepich M., et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol 26 (2008) 585-591
4. Lawton C.A., Winter K., Murry K., et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiotherapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49 (2001) 937-946
5. Laverdiere J., Gomez J.L., Cusan L., et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37 (1997) 247-252
6. Labrie F., Depont A., Cosun L., et al. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: The first controlled and randomized trial. Clin Invest Med (1993) 499-508
7. Soloway M.S., Sherif R., Wajsman Z., et al., for the Lupron Depot Neoadjuvant Prostate Cancer Study Group. A randomized prospective study comparing radical prostatectomy alone vs radical prostatectomy preceded by androgen blockade in clinical stage B2 prostate cancer. J Urol (1995) 424-428
8. Klotz L.H., Goldenberg S.L., Jewett M., et al., for the Canadian Urologic Oncology Group. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36 Month post-treatment PSA results. Urology 53 (1999) 752-763
9. Crook J., Ludgate C., Malone S., et al. Final report of a multicenter Canadian Phase III randomized trial of 3 vs 8 months neoadjuvant androgen deprivation before conventional-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 73 (2009) 327-333
10. Ludgate C., Bishop D., Pai H., et al. Neoadjuvant hormone therapy and external beam radiotherapy for localized high risk prostate cancer: The importance of PSA nadir before radiation. Int J Radiat Oncol Biol Phys 62 (2005) 1309-1315
11. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. J Am Med Assoc 280 (1998) 969-974
12. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
13. Goldenberg S.L., Klotz L.H., Srigley J., et al., for the Canadian Urologic Oncology Group. Randomized, prospective, controlled study comparing radical prostatectomy alone and neo-adjuvant androgen withdrawal in the treatment of localized prostate cancer. J Urol 156 (1996) 573-577
14. Joon D.L., Hasegawa M., Sikes C., et al. Supraadditive apoptotic response on R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 38 (1997) 1071-1077
15. Zeitman A.L., Prince E.A., Nakfoor B.M., et al. Androgen deprivation and radiotherapy: Sequencing studies using the Shinogi in vivo tumor system. Int J Radiat Oncol Biol Phys 38 (1997) 1076-1070
16. Heymann J.J., Benson M.C., O'Toole K.M., et al. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer. J Clin Onol 25 (2007) 77-84
17. Gleave M.E., Goldenberg S.L., Jones E.C., et al. Biochemical and pathologic effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 155 (1996) 213-219
18. Holzbeierlein J., McLaughlin L., Threasher J.B., et al. Complications of androgen deprivation therapy for prostate cancer. Curr Opin Urol 14 (2004) 177-183
19. Basaria S., Leib J., Tang A., et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrin 56 (2002) 779-786
20. Boxer R.S., Kenny A.M., Dowsett R., et al. The effect of 6 months of androgen deprivation on muscle and fat mass in older men with localized prostate cancer. Aging Male 8 (2005) 207-213
21. Chen Z., Maricic M., Nguyen P., et al. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer 95 (2002) 2136-2144
22. D'Amico A.V., Manola J., Loffredo M., et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. J Am Med Assoc 292 (2004) 821-827
23. Cahlon O., Zelefsky Amols H., et al. Ultra high dose (86.4Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 71 (2008) 330-337
24. Peeters S.T.H., Heemsbergen W.D., Kper P.C.M., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68Gy of radiotherapy with 78Gy. J Clin Oncol 24 (2006) 1990-1996
25. Pollack A., Zagars G.K., Smith L.G., et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70Gy with 78Gy for prostate cancer. J Clin Oncol 18 (2000) 3904-3911